Table 5.
All Subjects n = 12, n (%) | |
---|---|
All treatment‐emergent adverse events | 5 (41.7) |
Fall * | 2 (16.7) |
Musculoskeletal pain | 2 (16.7) |
Upper respiratory tract infection | 2 (16.7) |
Diabetes mellitus * | 1 (8.3) |
Fatigue | 1 (8.3) |
Hypercholesterolaemia | 1 (8.3) |
Hypophosphatemia | 1 (8.3) |
Rectal haemorrhage * | 1 (8.3) |
Vertigo positional * | 1 (8.3) |
Preferred terms were coded using MedDRA version 16.1.
Not related to investigational product.